Filing Analysis
Cardiff Oncology reported the results of its Annual Meeting of Stockholders held on June 11, 2026. The company successfully elected its board of directors, ratified its accounting firm, and approved an increase in shares for its Equity Incentive Plan.
🚩 Red Flags
- Proposal 3 (Equity Incentive Plan increase) showed significant opposition, with 8,063,520 shares voting against the measure, indicating some shareholder dissatisfaction with potential dilution.
📋 Key Facts
- Annual Meeting held on June 11, 2026, with 41,614,848 shares represented (quorum).
- All six director nominees were elected to serve until the 2027 Annual Meeting.
- BDO USA, P.C. was ratified as the independent registered public accounting firm for fiscal year 2026.
- Stockholders approved increasing the 2021 Equity Incentive Plan to 15,150,000 shares.
- Executive compensation received an advisory approval vote.
Cardiff Oncology, Inc. filed a current report to disclose an investor presentation regarding Phase 2 CRDF-004 data and registrational study plans for its drug candidate, onvansertib.
📋 Key Facts
- The filing date is June 3, 2026.
- The company presented Phase 2 CRDF-004 data.
- The presentation outlines registrational study plans for onvansertib.
- The materials were furnished as Exhibit 99.1 and are not deemed 'filed' under Section 18 of the Exchange Act.
Cardiff Oncology is engaged in a legal dispute with Nerviano Medical Sciences S.r.l. (NMS) over patent inventorship and development efforts. On May 27, 2026, NMS formally notified the company of its intent to terminate their March 13, 2017 License Agreement, alleging material breaches.
🚩 Red Flags
- Termination of a core License Agreement by a partner
- Active litigation in U.S. District Court
- Allegations of failure to use 'Commercially Reasonable Efforts' in drug development
- Dispute over patent inventorship which could impact intellectual property ownership
📋 Key Facts
- NMS issued a written notice of termination of the License Agreement on May 27, 2026, citing Section 11.3.
- NMS alleges breach of Section 10.2(c) regarding the failure to include Dr. Barbara Valsasina as a joint inventor on U.S. Pat. Nos. 12,144,813 and 12,263,173.
- NMS further alleges failure to use 'Commercially Reasonable Efforts' for development and regulatory approvals of onvansertib (Sections 7.3, 7.5, and 7.9).
- Cardiff Oncology filed a lawsuit against NMS on May 19, 2026, in the Southern District of California seeking injunctive relief and a declaratory judgment.
- The company maintains that the termination notice is 'legally ineffective, factually unsupported and procedurally improper'.
Cardiff Oncology, Inc. filed a lawsuit on May 19, 2026 against Nerviano Medical Sciences S.r.L (NMS) in the U.S. District Court for the Southern District of California, disputing NMS's allegation that Cardiff materially breached their license agreement for onvansertib, the company's lead drug candidate. Cardiff seeks injunctive relief to compel NMS to continue performing under the agreement and a declaratory judgment that no breach occurred. The dispute centers on inventorship rights related to two Cardiff patents (U.S. Patent Nos. 12,144,813 and 12,263,173), with NMS alleging Cardiff failed to name an NMS employee as a joint inventor.
🚩 Red Flags
- License agreement for onvansertib — Cardiff's lead drug candidate — is at risk of termination if NMS prevails in litigation
- NMS alleged material breach as far back as February 24, 2026; escalation to litigation suggests settlement discussions have failed
- Loss of the onvansertib license could be existential for a micro-cap oncology company with a single lead asset
- Cardiff's need for injunctive relief implies NMS may already be threatening to suspend or terminate performance under the agreement
- Inventorship dispute could cloud the validity and enforceability of Cardiff's key patents (Nos. 12,144,813 and 12,263,173)
- USPTO inventorship integrity concern: Cardiff explicitly states naming NMS employee would be 'false or inaccurate' — potential IP litigation complexity
📋 Key Facts
- Lawsuit filed May 19, 2026 in U.S. District Court for the Southern District of California against Nerviano Medical Sciences S.r.L (NMS)
- Dispute concerns the license agreement for onvansertib, Cardiff's key oncology asset
- NMS alleged material breach in a written notice dated February 24, 2026, roughly 3 months before litigation was initiated
- NMS claims Cardiff failed to name an NMS employee as joint inventor on U.S. Patent Nos. 12,144,813 and 12,263,173
- NMS also alleges Cardiff refused to file a joint invention continuation patent application
- Cardiff maintains it made no breach, asserting inventions were made exclusively by Cardiff and NMS employee listing would constitute false/inaccurate representations to the USPTO
- Cardiff seeks injunctive relief to keep NMS performing under the license agreement and a declaratory judgment of non-breach
- Filing signed by CEO Mani Mohindru; filed under Item 8.01 (Other Events)
Cardiff Oncology, Inc. reported its financial results for the first quarter ended March 31, 2026, and provided a business update. The details were released via a press release on May 14, 2026.
🚩 Red Flags
- The company is currently operating under an Interim CEO, which may indicate a period of management transition.
📋 Key Facts
- Financial results for the quarter ended March 31, 2026, were announced on May 14, 2026.
- The company furnished a press release as Exhibit 99.1.
- The filing was signed by Mani Mohindru in the capacity of Interim Chief Executive Officer.
Cardiff Oncology announced a comprehensive leadership restructuring, appointing a permanent CEO and hiring a new CFO and COO. Mani Mohindru, Ph.D., transitioned from Interim CEO to permanent President and CEO, while Josh Muntner and Ajay Aggarwal were appointed as CFO and COO, respectively.
🚩 Red Flags
- Simultaneous turnover/appointment of the entire C-suite (CEO, CFO, and COO) suggests a period of significant internal transition or prior instability.
📋 Key Facts
- Mani Mohindru, Ph.D. appointed permanent President and CEO with a base salary of $655,000 and a $100,000 bonus.
- Josh Muntner appointed CFO effective April 6, 2026, with a base salary of $475,000 and 486,650 stock options at an exercise price of $1.58.
- Ajay Aggarwal, MD, MBA appointed COO effective April 27, 2026, with a base salary of $490,000 and 400,000 expected stock options.
- Dr. Mohindru received two stock option grants in early 2026 totaling 800,000 shares with exercise prices of $1.56 and $1.62.
- All three executives are eligible for annual discretionary bonuses ranging from 40% to 55% of their base salaries.
Cardiff Oncology finalized separation agreements for its former CEO, Dr. Mark Erlander, and CFO, James Levine, following their departures in January 2026. The agreements involve significant severance payments and the resignation of Dr. Erlander from the Board of Directors as part of a strategic review.
🚩 Red Flags
- Simultaneous departure of both the Chief Executive Officer and Chief Financial Officer.
- Departures occurred in the context of a 'strategic review,' which often signals underlying operational or financial distress.
- Substantial cash severance obligations exceeding $1.1 million in base salaries alone for a micro-cap entity.
📋 Key Facts
- Former CEO Dr. Mark Erlander will receive a base salary of $635,000 over 12 months and a 2025 bonus of $122,238.
- Former CFO James Levine will receive a base salary of $490,000 over 12 months and a 2025 bonus of $61,740.
- Dr. Erlander resigned from the Board of Directors effective March 27, 2026.
- Both executives are entitled to 50% of their 2026 target bonuses on a pro-rated basis and 12 months of healthcare benefits.
- Dr. Erlander entered into a consulting agreement with the company, with stock options continuing to vest until June 2026.
- The departures were previously disclosed on January 26, 2026, as part of a 'strategic review'.
Cardiff Oncology, Inc. furnished a corporate slide presentation under Regulation FD for use in upcoming meetings with third parties. The filing includes the presentation as Exhibit 99.1 and was signed by the Interim CEO.
🚩 Red Flags
- The company is currently operating under an Interim CEO (Mani Mohindru), which may indicate leadership transition or instability.
📋 Key Facts
- The filing was made on February 25, 2026, under Item 7.01 Regulation FD Disclosure.
- The company intends to use the corporate slide presentation in meetings with third parties.
- Mani Mohindru is identified as the Interim Chief Executive Officer.
- The information in the report is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
Cardiff Oncology announced its full-year 2025 financial results and provided a business update on February 24, 2026. The report was signed by Mani Mohindru in the capacity of Interim Chief Executive Officer.
🚩 Red Flags
- The company is currently led by an Interim CEO, indicating a period of leadership transition.
📋 Key Facts
- Financial results for the full year ended December 31, 2025 were released on February 24, 2026.
- The filing includes a business update alongside the financial data.
- Mani Mohindru is currently serving as the Interim Chief Executive Officer.
- The press release is furnished as Exhibit 99.1 under Item 9.01.